NVOH - ETF AI Analysis
Top Page
Novo Nordisk A/S (B Shares) ADRhedged (NVOH)
Rating:71Outperform
Price Target:―
Positive Factors
Recent Short-Term Rebound
The ETF has shown strong gains over the past one and three months, suggesting improving short-term momentum despite a weaker year-to-date result.
Focused Exposure to a Leading Healthcare Name
The fund is heavily invested in Novo Nordisk, a major healthcare company, giving investors targeted exposure to a well-known player in the sector.
Low Expense Ratio
The ETF charges a relatively low fee, which helps investors keep more of their returns over time.
Negative Factors
High Single-Stock Concentration
With nearly all assets in one company, investors face elevated risk if that single stock performs poorly.
Year-to-Date Underperformance
The ETF’s overall performance so far this year has been weak, reflecting recent softness in its main holding.
Limited Sector and Geographic Diversification
The fund is concentrated in U.S.-listed healthcare exposure, offering little protection if that sector or region experiences a downturn.
NVOH vs. SPDR S&P 500 ETF (SPY)
AUM4.03M
RegionEurope
Expense Ratio0.19%
Beta1.01
IssuerADRhedged
Inception DateJan 07, 2025
Dividend Yield6.57%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume760
30 Day Avg. Volume1,539
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
24.14Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NVOH Summary
NVOH is an ETF that focuses on Novo Nordisk, a major global healthcare and pharmaceutical company known for its diabetes and obesity treatments. It doesn’t track a broad index, but instead gives targeted exposure to this single company, while using a currency hedge to reduce the impact of foreign exchange swings for U.S. investors. Someone might invest in NVOH if they believe Novo Nordisk will continue to grow as demand for specialized healthcare and chronic disease treatments increases. A key risk is that the ETF is heavily concentrated in one company, so its value can rise or fall sharply with Novo Nordisk’s fortunes.
How much will it cost me?The NVOH ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed funds, as it focuses on a specific company and niche within the healthcare sector, keeping costs relatively modest.
What would affect this ETF?The NVOH ETF could benefit from the growing global demand for innovative healthcare solutions, particularly in diabetes and obesity treatments, areas where Novo Nordisk is a leader. However, potential risks include regulatory changes in the pharmaceutical industry or shifts in healthcare policies that could impact drug pricing and market access. Additionally, while the fund mitigates currency risk, broader economic challenges in Europe or Denmark could still influence its performance.
NVOH Top 10 Holdings
This ETF is essentially a one-stock story, with Novo Nordisk doing almost all the heavy lifting. The fund is tightly tied to the health care and pharmaceuticals theme, and its fate rises or falls with Novo’s share price. Recently, the stock has been a bit mixed—earlier strength has given way to some choppier, slightly lagging action as technical signals cool and worries about market share and restructuring creep in. With its Europe-heavy, Denmark-focused exposure, this is less a diversified basket and more a single, high-conviction bet on Novo’s long-term growth.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novo Nordisk | 96.43% | $3.87M | $185.59B | -30.17% | 73 Outperform |
NVOH Technical Analysis
Negative
―
Price Trends
25.43
Negative
24.86
Negative
24.42
Negative
Market Momentum
-0.52
Positive
42.94
Neutral
43.35
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NVOH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 24.53, equal to the 50-day MA of 25.43, and equal to the 200-day MA of 24.42, indicating a bearish trend. The MACD of -0.52 indicates Positive momentum. The RSI at 42.94 is Neutral, neither overbought nor oversold. The STOCH value of 43.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVOH.
NVOH Peer Comparison
Comparison Results
Performance Comparison
NVOH
Novo Nordisk A/S (B Shares) ADRhedged
23.74
-6.90
-22.52%
ASMH
ASML Holding NV ADRhedged
―
―
―
ARMH
Arm Holdings PLC ADRhedged
―
―
―
HSBH
HSBC Holdings plc ADRhedged
―
―
―
BPH
BP p.l.c. ADRhedged
―
―
―
GSKH
GSK plc ADRhedged
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents